Global Peptide Therapeutics Market & Clinical Trials Insight 2022

Publish Date:- May-2017       No Of Pages (1300)

Electronic Access - Single User License $3000 Buy Now
CD-ROM Mail Delivery $3600Buy Now
Hard Copy Mail Delivery $4200 Buy Now
Electronic Access - Multi-User License $6000 Buy Now


“Global Peptide Therapeutics Market & Clinical Trials Insight 2022” report gives comprehensive insight into the various clinical and non-clinical issues involved in the development of global peptide drug market.  In recent years, peptides have emerged as one of the important classes of therapeutic molecules which have been developed by varied pharmaceutical and biotech companies in order to attain a targeted drug discovery for several ailments. As per report findings, there are 688 peptide drugs in clinical pipeline and more than 100 peptide based drugs commercially available in the market.

Research and development of peptide based therapeutics has gained significant momentum in past several decades due to high safety and efficacy profiles. This drives the pharmaceutical companies to invest more in this segment to come forth with competitive products for marketing. Owing to large number of diseases indications they have potential to occupy large market shares and generate significant amount of revenues. Pharmaceutical companies focused their efforts to tap this market segment by investing more funds in research and development activities. As a result, newer peptide based therapeutics are entering in global market and others are at various phases of clinical trials which are expected to get marketing approval in near future. Increased competition with drugs belonging to other categories for same disease indication is also expected to increase with time in this segment.

Peptides are used in drug development programs to provide superior pharmacological effects and alleviate patient medical condition. They have high safety and efficacy due to which they are widely accepted among physicians and patients for treatment of various ailments. In clinical practice, they are used for diabetes, various kinds of cancers, infectious diseases, cardiovascular and many other diseases indications. They could be easily modified as compared to other drug categories making them highly profitable for sponsors. Due to versatility they could be used for several medical indications leading to higher market penetration. Besides therapeutics effects, mature market give advantages related to familiarity and relatively easy marketing approval.

 

“Global Peptide Therapeutics Market & Clinical Trials Insight 2022” report highlight

  • Fundamentals of Peptide Therapeutics
  • Peptide Therapeutics by Applications & Indications
  • Peptides Clinical Trials Insight by Phase, Indication & Company
  • Insight on 688 Peptide Drugs in Clinical Trials
  • Clinical & Patent Insight on 119 Marketed Peptides
  • Future Peptide Therapeutics Market Outlook

 

Peptide drugs are versatile in nature due to which they can be used for treating various life threatening diseases. Modifications to achieve superior pharmacological effect are relatively easy due to which they can be introduced in market for different diseases categories. Pharmaceutical companies can generate significant revenues in global market due to this property. Diabetes, Central Nervous System (CNS), hormonal systems, cardiovascular diseases, oncology and other diseases have effective peptide based therapeutics. Potential of generating significant revenues by these drugs by pharmaceutical companies is expected to cause increase funding in research and development segment. Market size of these drugs is expected to increase several folds in near future as more innovative drugs for multiple diseases indications would be introduced in market in coming years.

Rapidly increasing number of clinical trials reflects the unmet demand for better for peptide therapeutics for patients. Due to escalating disease incidences, it has become imperative to take necessary steps to introduce innovative peptide based therapeutics rapidly in global market. Some therapeutics like GLP-1 is expected substitute for insulin which has one of the largest market size and widespread acceptability among patients and physicians. But pharmacological efficacy of this innovative drug is clinically equivalent to insulin with additional benefit of regulation which is not found in its counterpart. Market success rates of new peptide based therapeutics will depend on the significance of data generated during clinical trials and effectiveness of marketing strategy. 


“Global Peptide Therapeutics Market & Clinical Trials Insight 2022” report gives comprehensive insight into the various clinical and non-clinical issues involved in the development of global peptide drug market.  In recent years, peptides have emerged as one of the important classes of therapeutic molecules which have been developed by varied pharmaceutical and biotech companies in order to attain a targeted drug discovery for several ailments. As per report findings, there are 688 peptide drugs in clinical pipeline and more than 100 peptide based drugs commercially available in the market.

Research and development of peptide based therapeutics has gained significant momentum in past several decades due to high safety and efficacy profiles. This drives the pharmaceutical companies to invest more in this segment to come forth with competitive products for marketing. Owing to large number of diseases indications they have potential to occupy large market shares and generate significant amount of revenues. Pharmaceutical companies focused their efforts to tap this market segment by investing more funds in research and development activities. As a result, newer peptide based therapeutics are entering in global market and others are at various phases of clinical trials which are expected to get marketing approval in near future. Increased competition with drugs belonging to other categories for same disease indication is also expected to increase with time in this segment.

Peptides are used in drug development programs to provide superior pharmacological effects and alleviate patient medical condition. They have high safety and efficacy due to which they are widely accepted among physicians and patients for treatment of various ailments. In clinical practice, they are used for diabetes, various kinds of cancers, infectious diseases, cardiovascular and many other diseases indications. They could be easily modified as compared to other drug categories making them highly profitable for sponsors. Due to versatility they could be used for several medical indications leading to higher market penetration. Besides therapeutics effects, mature market give advantages related to familiarity and relatively easy marketing approval.

 

“Global Peptide Therapeutics Market & Clinical Trials Insight 2022” report highlight

  • Fundamentals of Peptide Therapeutics
  • Peptide Therapeutics by Applications & Indications
  • Peptides Clinical Trials Insight by Phase, Indication & Company
  • Insight on 688 Peptide Drugs in Clinical Trials
  • Clinical & Patent Insight on 119 Marketed Peptides
  • Future Peptide Therapeutics Market Outlook

 

Peptide drugs are versatile in nature due to which they can be used for treating various life threatening diseases. Modifications to achieve superior pharmacological effect are relatively easy due to which they can be introduced in market for different diseases categories. Pharmaceutical companies can generate significant revenues in global market due to this property. Diabetes, Central Nervous System (CNS), hormonal systems, cardiovascular diseases, oncology and other diseases have effective peptide based therapeutics. Potential of generating significant revenues by these drugs by pharmaceutical companies is expected to cause increase funding in research and development segment. Market size of these drugs is expected to increase several folds in near future as more innovative drugs for multiple diseases indications would be introduced in market in coming years.

Rapidly increasing number of clinical trials reflects the unmet demand for better for peptide therapeutics for patients. Due to escalating disease incidences, it has become imperative to take necessary steps to introduce innovative peptide based therapeutics rapidly in global market. Some therapeutics like GLP-1 is expected substitute for insulin which has one of the largest market size and widespread acceptability among patients and physicians. But pharmacological efficacy of this innovative drug is clinically equivalent to insulin with additional benefit of regulation which is not found in its counterpart. Market success rates of new peptide based therapeutics will depend on the significance of data generated during clinical trials and effectiveness of marketing strategy. 

1. A Revolution of Peptide Therapeutics

  1.1 Peptides as Drug Candidates

  1.2 Necessity of Peptide Therapeutics

 

2. Cusp of Small Molecules & Proteins

  2.1 Peptides v/s Small Molecules

  2.2 Peptides v/s Protein Biologics

 

3. Fundamentals of Peptide Therapeutics

  3.1 Rational Design for Novel Peptides

  3.2 Aspects of Regulatory Approvals

 

4. Peptide Therapeutics by Applications

  4.1 Application of Peptides in Imaging

  4.2 Application of Peptides in Diseases

 

5. Peptide Therapeutics in Metabolic Disorder

  5.1 Prologue Metabolic Disorders

  5.2 Approved Peptide Drugs for Metabolic Disorders

  5.3 Market of Metabolic Peptides

 

6. Peptide Therapeutics in Cancer

6.1 Prologue to Cancer

6.2 Approved Peptide Drugs in Cancer Therapeutics

6.3 Market of Cancer Peptides

 

7. Peptide Therapeutics in Cardiovascular

  7.1 Prologue to Cardiovascular Diseases

  7.2 Approved Peptide Drugs in Cardiovascular Diseases

  7.3 Market of Cardiac Peptides

 

8. Peptide Therapeutics in HIV & Infections

  8.1 Prologue to Infections

  8.2 Approved Peptide Therapeutics in Infections

  8.3 Market of Anti-Infectious Peptides

 

9. Peptide Therapeutics in CNS Disorders

  9.1 Prologue to CNS Disorders

  9.2 Neuropeptides Drug Delivery to CNS

  9.3 Future Market Potential

 

10. Global Peptide Therapeutics Market

  10.1 Prologue to the Peptide Market

  10.2 Peptide Market by Application

 

11. Global Peptide Market by Administration

  11.1 Current Trends in Route of Administration

  11.2 Current Trends over the Peptide Products

 

12. Global Peptides Clinical Trials Overview

  12.1 Cyclic Peptides

  12.2 Depsipeptides

  12.3 Dipeptides

  12.4 Glucagon-Like Peptides

  12.5 Lipopeptides

  12.6 Natriuretic Peptides

  12.7 Neuropeptides Peptides

  12.8 Oligopeptides

  12.9 Opioid Peptides

  12.10 Peptides

  12.11 Peptide Hormones

  12.12 Peptide Fragments

  12.13 Multiple Peptides

 

13. Global Peptide Market by Region

  13.1 North America

  13.2 Europe

  13.3 Asia

 

14. Global Peptide Market Dynamics

  14.1 Favorable Parameters

  14.2 Challenges

 

15. Future Peptide Therapeutics Market Outlook

  15.1 Future Trends in Peptide Therapeutics

  15.2 Future Opportunities of Peptides Therapeutics

 

16. Cyclic Peptides Clinical Trials Insight by Phase, Indication & Company

  16.1 Research till Preregistration

  16.2 Marketed

 

17. Depsipeptides Clinical Trials Insight by Phase, Indication & Company

  17.1 Preclinical till Preregistration

  17.2 Marketed

 

18. Dipeptides Clinical Trials Insight by Phase, Indication & Company

  18.1 Preclinical till Registered

  18.2 Marketed

 

19. Glycopeptides Clinical Trials Insight by Phase, Indication & Company

  19.1 Preclinical till Phase-I

 

20. Glucagon-Like Peptides Clinical Trials Insight by Phase, Indication & Company

  20.1 Resarch till Phase-III

  20.2 Marketed

 

21. Lipopeptides Clinical Trials Insight by Phase, Indication & Company

  21.1 Preclinical till Phase-II

 

22. Natriuretic Peptides Clinical Trials Insight by Phase, Indication & Company

  22.1 Preclinical till Phase-III

  22.2 Marketed

 

23. Neuropeptides Clinical Trials Insight by Phase, Indication & Company

  23.1 Preclinical till Phase-III

  23.2 Marketed

 

24. Oligopeptides Clinical Trials Insight by Phase, Indication & Company

  24.1 Preclinical till Registered

  24.2 Marketed

 

25. Opioid Peptides Clinical Trials Insight by Phase, Indication & Company

  25.1 Preclinical till Preregistration

  25.2 Marketed

 

26. Peptides Clinical Trials Insight by Phase, Indication & Company

  26.1 Research till Registered

  26.2 Marketed

 

27. Peptide Antibiotics Clinical Trials Insight by Phase, Indication & Company

  27.1 Research

 

28. Peptide Aptamers Clinical Trials Insight by Phase, Indication & Company

  28.1 Preclinical

 

29. Peptide Hormones Clinical Trials Insight by Phase, Indication & Company

  29.1 Research till Registered

  29.2 Marketed

 

30. Peptide Fragments Clinical Trials Insight by Phase, Indication & Company

  30.1 Research till Preregistration

  30.2 Marketed

 

31. Multiple Peptides Clinical Trials Insight by Phase, Indication & Company

  31.1 Research till Preregistration

  31.2 Marketed

 

32. Competitive Landscape

  32.1 Amgen

  32.2 Amylin Pharmaceuticals

  32.3 Apitope Technology

  32.4 BioPartners

  32.5 BiondVax Pharmaceuticals Ltd

  32.6 Boehringer Ingelheim

  32.7 Circassia

  32.8 Corden Pharma (Peptisyntha)

  32.9 Eli Lily

  32.10 Galena Biopharmaceuticals

  32.11 GlaxoSmithKline

  32.12 Hyperion Therapeutics

  32.13 ImmunoCellular Therapeutics

  32.14 Ipsen

  32.15 Lonza

  32.16 Merck

  32.17 NovoNordisk

  32.18 Par Pharmaceuticals

  32.19 PeptiDream

  32.20 Roche

  32.21 Sanofi

  32.22 Tarix Pharmaceuticals


Figure 2-1: Peptides as a Cusp of Small Molecule Drug & Proteins

Figure 2-2: Layout of Advantages of Peptide Drugs

Figure 3-1: Classification Based over the Sources of Peptide

Figure 3-2: Strategies for Screening of Novel peptides for Therapeutic Use

Figure 3-3: Methods for Generating Peptide Therapeutics at Large Scale

Figure 3-4: Whole General Concept of Manufacturing of Peptide Drugs

Figure 3-5: Process of Peptide Therapeutics FDA Approval Path

Figure 4-1: Diagrammatic Representation of the Peptidic Probe

Figure 4-2: Distribution of Therapeutic Drugs Approved by FDA by Chemical Species

Figure 5-1: Layout of Metabolic Syndrome Leading to Several Diseases

Figure 5-2: Global - Top 10 Countries with Diabetes Burden (Million), 2030

Figure 5-3: Obesity - Estimated Prevalence by Country (2025)

Figure 5-4: US– GLP-1 Agonist Drugs Cost Comparison (US$)

Figure 5-5: Lantus – Monthly Cost Comparison by Country (US$)

Figure 5-6: Global - Metabolic Disorders Peptide Drug Market (US$ Billion)

Figure 5-7: Victoza - GLP-1 Value Market Percentage Share of Total Diabetic Care Market

Figure 6-1: Global - All Cancer Rates Cases per 100,000 People by Top 10 Country

Figure 6-2: Global - Cancer Peptide Therapeutics Market (US$ Billion), 2014 & 2020

Figure 6 3: Global - Velcade Market Sales (US$ Billion)

Figure 6-4: US – Velcade Sales (US$ Billion), 2016 & 2022

Figure 6-5: Global - Kyprolis Revenues (US$ Billion), 2013 - 2017

Figure 6-6: Global & US - Zoladex Sales (US$ Million), 2016

Figure 7-1: Global & US - Angiomax Sales (US$ Million)

Figure 7-2: Global - Integrilin Sales (US$ Million), 2016

Figure 8-1: Global - Top 10 Leading Causes of Death

Figure 8-2: Global – HIV Prevalence among Varied Regions

Figure 8-3: Fuzeon - Global Sales (US$ Millions), 2016

Figure 9-1: US - Prevalence of Alzheimer’s disease (Millions)

Figure 10-1: Global - Peptide Drug Market (US$ Billion), 2014-2022

Figure 11-1: Therapeutic Peptide Based Drugs over Route of Administration

 Figure 12-1: Global – All Peptides Clinical Pipeline by Phase (%), 2017 till 2022

 Figure 12-2: Global - All Peptides Clinical Pipeline by Phase (Number), 2017 till 2022

 Figure 12-3: Global - Cyclic Peptides Clinical Pipeline by Phase (%), 2017 till 2022

 Figure 12-4: Global - Cyclic Peptides Clinical Pipeline by Phase (Number), 2017 till

 2022

 Figure 12-5: Global - Depsipeptides Peptides Clinical Pipeline by Phase (%), 2017 till

 2022

 Figure 12-6: Global - Depsipeptides Peptides Clinical Pipeline by Phase (Number), 2017

 till 2022

 Figure 12-7: Global - Dipeptides Peptides Clinical Pipeline by Phase (%), 2017 till 2022

 Figure 12-8: Global - Dipeptides Peptides Clinical Pipeline by Phase (Number), 2017

  till 2022

 Figure 12-9: Global - Glucagon-Like Peptides Clinical Pipeline by Phase (%), 2017 till

 2022

 Figure 12-10: Global - Glucagon-Like Peptides Clinical Pipeline by Phase (Number),  

 2017 till 2022

 Figure 12-11: Global - Lipopeptides Peptides Clinical Pipeline by Phase (%), 2017 till

 2022

 Figure 12-12: Global - Lipopeptides Peptides Clinical Pipeline by Phase (Number), 2017

 till 2022

 Figure 12-13: Global - Natriuretic Peptides Clinical Pipeline by Phase (%), 2017 till

 2022

 Figure 12-14: Global - Natriuretic Peptides Clinical Pipeline by Phase (Number), 2017 till 2022

 Figure 12-15: Global - Neuropeptides Peptides Clinical Pipeline by Phase (%), 2017 till

 2022

 Figure 12-16: Global - Neuropeptides Peptides Clinical Pipeline by Phase (Number),

 2017 till 2022

 Figure 12-17: Global - Oligopeptides Peptides Clinical Pipeline by Phase (%), 2017 till

 2022

 Figure 12-18: Global - Oligopeptides Peptides Clinical Pipeline by Phase (Number),

 2017 till 2022

 Figure 12-19: Global - Opioid Peptides Clinical Pipeline by Phase (%), 2017 till 2022

 Figure 12-20: Global - Opioid Peptides Clinical Pipeline by Phase (Number), 2017 till

 2022

 Figure 12-21: Global - Peptides Clinical Pipeline by Phase (%), 2017 till 2022

 Figure 12-22: Global - Peptides Clinical Pipeline by Phase (Number), 2017 till 2022

 Figure 12-23: Global - Peptide Hormones Clinical Pipeline by Phase (%), 2017 till 2022

 Figure 12-24: Global - Peptide Hormones Clinical Pipeline by Phase (Number), 2017 till

 2022

 Figure 12-25: Global - Peptide Fragments Clinical Pipeline by Phase (%), 2017 till 2022

 Figure 12-26: Global - Peptide Fragments Clinical Pipeline by Phase (Number), 2017

 till 2022

 Figure 12-27: Global - Multiple Peptides Clinical Pipeline by Phase (%), 2017 till 2022

 Figure 12-28: Global - Multiple Peptides Clinical Pipeline by Phase (Number), 2017 till

 2022

 Figure 14-1: Illustration of Peptide Therapeutics Market Drivers

 Figure 14-2: Major Challenges Faced by the Peptide Therapeutics

 Figure 15-1: Future Trends of Peptide Therapeutics